Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (5135)	12/13/2001 4:37:25 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Yes indeed - I had some PCYC calls that are now toast. This used to be a substantial holding for me, but I bailed when doubt was cast on their preclinical data. I re-entered with some calls a few months back (with the stock around $16) because I felt the risk-reward was reasonable. Well, looks like I got the risk and no reward. <g> Here's a link to an earlier post on this thread describing the controversy surrounding Xcytrin: Message 16645739 Peter